The commercialisation of psychedelics: patents and startups

The current psychedelic renaissance has moved well beyond university laboratories and underground therapy circles. Over the past decade, a substantial industry has emerged, with for-profit startups raising billions in capital to develop psychedelic-based medicines. This rapid commercialisation has sparked a complex debate at the intersection of economics, law, and ethics. While private investment is accelerating clinical research and bringing potential new treatments closer to regulatory approval, it has also raised pressing questions about who gets to own these therapies, who will be able to afford them, and how to balance corporate profit with the public good.

The Rise of Psychedelic Startups

Developing a new pharmaceutical drug is an extraordinarily expensive process, often costing hundreds of millions of dollars to navigate the required preclinical research and clinical trials. Because public funding for psychedelic research has historically been scarce, private capital has filled the gap. Dozens of biotechnology companies have formed to develop patented formulations of psychedelic compounds, such as psilocybin, MDMA, and ketamine derivatives.

The business model for these startups typically relies on intellectual property. Because naturally occurring molecules like psilocybin have existed for millennia and cannot be patented in their natural form, companies seek patents on synthetic variations, specific methods of manufacturing, novel delivery systems, or proprietary therapeutic protocols used alongside the drug. This exclusivity is what makes the high-risk investment attractive to venture capitalists.

The Patent Controversy

The rush to patent psychedelic therapies has generated significant legal and ethical controversy. Critics, including some researchers and public-interest organisations, argue that many of these patents are overly broad or cover obvious modifications of existing knowledge. There is concern that companies are creating 'patent thickets'—webs of overlapping intellectual property designed to block competitors—which could stifle independent research and keep prices artificially high.

Several high-profile legal challenges have emerged in this space. Non-profit watchdog groups have actively filed petitions with patent offices to invalidate patents they believe were improperly granted, arguing that they privatise public science. The debate highlights a tension in pharmaceutical innovation: patents are designed to reward financial risk, but when applied to long-standing natural compounds and traditional practices, they can act as monopolies that hinder broader scientific progress.

Ethics, Indigenous Knowledge, and Access

The commercialisation of psychedelics also raises profound ethical questions regarding biopiracy and the appropriation of Indigenous knowledge. Compounds like psilocybin and mescaline have been used in spiritual and healing ceremonies by Indigenous communities for centuries. Many Indigenous advocates argue that western pharmaceutical companies are profiting from their traditional knowledge without adequate recognition, benefit-sharing, or respect for the sacred context of these medicines.

Furthermore, there are significant concerns about equitable access. If psychedelic-assisted therapies are eventually approved and brought to market as expensive, patent-protected treatments, they may only be accessible to the wealthy. Because mental health conditions disproportionately affect marginalised communities, a scenario where only the affluent can afford these therapies risks exacerbating existing health inequalities. This economic reality complicates the narrative of psychedelics as a universal breakthrough for public mental health.

The South African Context and the Cannabis Precedent

In South Africa, psilocybin is currently listed as a Schedule 7 substance under the Medicines and Related Substances Act, making it strictly illegal. However, should the South African Health Products Regulatory Authority (SAHPRA) ever consider rescheduling psilocybin for medical use in the future, the global patent landscape will inevitably influence local access. South African policymakers and health advocates are closely watching how commercialisation unfolds elsewhere to avoid similar pitfalls.

The commercialisation of psychedelics is often compared to the recent history of cannabis in South Africa. Following the legalisation of private cannabis cultivation for personal use, a booming commercial industry emerged. However, this has been accompanied by intense debates over regulatory frameworks, corporate monopolies, and the exclusion of traditional and informal growers. As the global psychedelic industry matures, South Africa faces similar questions about how to ensure that any future legal medical access prioritises public health and broad accessibility over the creation of monopolistic corporate empires.